Long-term health trajectories for Canadians with COPD

Summary

Client: AstraZeneca Canada/Broadstreet Health Economics

Project ID: P2020-069 / 2021 0970 226 000

Research Question/Objectives: The overall aim is to understand the impact of chronic obstructive pulmonary disease (COPD) exacerbations and the pattern of treatment to characterize disease trajectory and burden of disease among COPD patients in Canada, over time, from diagnosis to death, and how this may differ by treatment patterns. To characterize the frequency and time to exacerbations and other acute and chronic comorbidities, as well as healthcare resource uses, over a patient’s lifetime, in relation to their treatment.

Specifically, the research objectives of interest are:

• Characterize the health and treatment trajectories of patients with COPD from diagnosis to death.
• Assess clinical outcomes and healthcare resource use following moderate to severe COPD exacerbations (in the first year of follow-up), combined and stratified by severity of exacerbation (mild vs. severe).
• Characterize the health and treatment trajectories of patients with COPD between and within each treatment-bound time period (i.e. while on mono-, dual-, or triple-therapy).
• Describe the treatment patterns and burden of disease by different treatment groups at baseline (first year of follow-up).
• Describe burden of disease in different treatment groups, by treatment at baseline.
• Assess the impact of different treatment algorithms on patient, specifically on time to exacerbations and survival.
• Describe the association of early vs delayed treatment after COPD diagnosis with Fixed-Dose Combination (FDC) Triple and resource utilization/cost-saving.
• Describe the association of specific co-morbidities and exacerbations.
• Explore association of biomarkers with exacerbation risk, if available.

Results:

• February 2023